EPS for Cytokinetics, (CYTK) Expected At $-0.71; Energy Recovery (ERII) Has 1.35 Sentiment

January 14, 2018 - By Vivian Currie

Energy Recovery, Inc. provides energy solutions to industrial fluid flow markets under the ERI, PX, Pressure Exchanger, PX Pressure Exchanger, AT, AquaBold, VorTeq, IsoBoost, and IsoGen names worldwide. The company has market cap of $481.28 million. The firm operates through Water and Oil & Gas divisions. It has a 138.15 P/E ratio. It offers pressure exchanger energy recovery devices and turbocharger technologies for water desalination and gas and oil; AT turbochargers for low-pressure brackish, and high-pressure seawater reverse osmosis systems; and high-performance, high-efficiency, high-pressure, and circulation booster pumps.

Analysts expect Cytokinetics, Incorporated (NASDAQ:CYTK) to report $-0.71 EPS on February, 15.They anticipate $0.87 EPS change or 543.75% from last quarter’s $0.16 EPS. After having $-0.60 EPS previously, Cytokinetics, Incorporated’s analysts see 18.33% EPS growth. The stock increased 0.57% or $0.05 during the last trading session, reaching $8.85. About 181,252 shares traded. Cytokinetics, Incorporated (NASDAQ:CYTK) has risen 88.33% since January 14, 2017 and is uptrending. It has outperformed by 71.63% the S&P500.

Nokomis Capital L.L.C. holds 3.02% of its portfolio in Energy Recovery, Inc. for 1.42 million shares. Encompass Capital Advisors Llc owns 800,000 shares or 1.03% of their US portfolio. Moreover, 683 Capital Management Llc has 0.58% invested in the company for 700,100 shares. The New York-based Arosa Capital Management Lp has invested 0.56% in the stock. Heartland Advisors Inc, a Wisconsin-based fund reported 850,000 shares.

The stock increased 1.47% or $0.13 during the last trading session, reaching $8.98. About 203,159 shares traded. Energy Recovery, Inc. (ERII) has declined 27.39% since January 14, 2017 and is downtrending. It has underperformed by 44.09% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 1 insider sale for $22,000 activity.

Analysts await Energy Recovery, Inc. (NASDAQ:ERII) to report earnings on March, 14. They expect $0.32 EPS, up 433.33% or $0.26 from last year’s $0.06 per share. ERII’s profit will be $17.15M for 7.02 P/E if the $0.32 EPS becomes a reality. After $0.03 actual EPS reported by Energy Recovery, Inc. for the previous quarter, Wall Street now forecasts 966.67% EPS growth.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company has market cap of $476.88 million. The firm is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. It currently has negative earnings. The Company’s lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis.

Among 12 analysts covering Cytokinetics (NASDAQ:CYTK), 11 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Cytokinetics had 21 analyst reports since July 24, 2015 according to SRatingsIntel. The stock has “Buy” rating by Needham on Friday, October 27. MLV maintained the stock with “Buy” rating in Friday, July 24 report. The firm has “Buy” rating given on Tuesday, October 10 by Piper Jaffray. Needham upgraded Cytokinetics, Incorporated (NASDAQ:CYTK) on Monday, February 6 to “Strong Buy” rating. The stock of Cytokinetics, Incorporated (NASDAQ:CYTK) has “Outperform” rating given on Tuesday, November 10 by FBR Capital. Cowen & Co maintained it with “Buy” rating and $1900 target in Thursday, August 3 report. On Monday, November 9 the stock rating was maintained by TH Capital with “Buy”. The firm has “Neutral” rating by Cantor Fitzgerald given on Wednesday, November 22. The stock of Cytokinetics, Incorporated (NASDAQ:CYTK) earned “Buy” rating by Needham on Wednesday, July 27. Cantor Fitzgerald initiated it with “Overweight” rating and $21 target in Friday, December 16 report.

Investors sentiment decreased to 1.39 in 2017 Q3. Its down 1.55, from 2.94 in 2017Q2. It dropped, as 16 investors sold Cytokinetics, Incorporated shares while 30 reduced holdings. 21 funds opened positions while 43 raised stakes. 39.12 million shares or 3.53% more from 37.79 million shares in 2017Q2 were reported. Schwab Charles Invest Mngmt accumulated 303,347 shares. Wellington Mgmt Gp Ltd Liability Partnership reported 2.32M shares. Bank & Trust Of Montreal Can invested 0% in Cytokinetics, Incorporated (NASDAQ:CYTK). Public Sector Pension Board, a Quebec – Canada-based fund reported 32,241 shares. Wasatch Advsrs Inc owns 0.14% invested in Cytokinetics, Incorporated (NASDAQ:CYTK) for 702,672 shares. Blackrock Inc stated it has 0.01% in Cytokinetics, Incorporated (NASDAQ:CYTK). Grp One Trading Lp, a Illinois-based fund reported 66,057 shares. Mason Street Advisors Ltd Liability has 0% invested in Cytokinetics, Incorporated (NASDAQ:CYTK). Arizona State Retirement Systems holds 0% in Cytokinetics, Incorporated (NASDAQ:CYTK) or 26,200 shares. Lansdowne (Uk) Limited Liability Partnership reported 0.4% in Cytokinetics, Incorporated (NASDAQ:CYTK). Dimensional Fund Advisors L P stated it has 0% of its portfolio in Cytokinetics, Incorporated (NASDAQ:CYTK). Vanguard Gru stated it has 3.39 million shares. Lenox Wealth Management Inc has invested 0% in Cytokinetics, Incorporated (NASDAQ:CYTK). Guggenheim Limited Com reported 123,456 shares or 0% of all its holdings. Metropolitan Life Ins has 0% invested in Cytokinetics, Incorporated (NASDAQ:CYTK).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Vivian Currie







Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: